Navamedic Past Earnings Performance
Past criteria checks 1/6
Navamedic has been growing earnings at an average annual rate of 57.2%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 24.8% per year. Navamedic's return on equity is 7.4%, and it has net margins of 3.7%.
Key information
57.2%
Earnings growth rate
72.4%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | 24.8% |
Return on equity | 7.4% |
Net Margin | 3.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Navamedic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 526 | 20 | 69 | 0 |
30 Jun 24 | 543 | 27 | 67 | 0 |
31 Mar 24 | 511 | -11 | 68 | 0 |
31 Dec 23 | 512 | 3 | 64 | 0 |
30 Sep 23 | 503 | 31 | 80 | 0 |
30 Jun 23 | 454 | 23 | 101 | 0 |
31 Mar 23 | 441 | 43 | 57 | 0 |
31 Dec 22 | 382 | 29 | 48 | 0 |
30 Sep 22 | 356 | 12 | 59 | 0 |
30 Jun 22 | 327 | 8 | 47 | 0 |
31 Mar 22 | 283 | 4 | 49 | 0 |
31 Dec 21 | 278 | 1 | 44 | 0 |
30 Sep 21 | 244 | -7 | 50 | 0 |
30 Jun 21 | 237 | -6 | 38 | 0 |
31 Mar 21 | 213 | -8 | 46 | 0 |
31 Dec 20 | 210 | -16 | 33 | 0 |
30 Sep 20 | 202 | -22 | 58 | 0 |
30 Jun 20 | 194 | -24 | 33 | 0 |
31 Mar 20 | 199 | -26 | 34 | 0 |
31 Dec 19 | 189 | -16 | 33 | 0 |
30 Sep 19 | 193 | -1 | 32 | 0 |
30 Jun 19 | 189 | 0 | 27 | 0 |
31 Mar 19 | 187 | 10 | 25 | 0 |
31 Dec 18 | 184 | 4 | 26 | 0 |
30 Sep 18 | 177 | -20 | 30 | 0 |
30 Jun 18 | 178 | -13 | 28 | 0 |
31 Mar 18 | 222 | -20 | 30 | 0 |
31 Dec 17 | 258 | -16 | 30 | 0 |
30 Sep 17 | 294 | 3 | 31 | 0 |
30 Jun 17 | 315 | 4 | 32 | 0 |
31 Mar 17 | 292 | -9 | 31 | 0 |
31 Dec 16 | 274 | -11 | 31 | 0 |
30 Sep 16 | 258 | -28 | 31 | 0 |
30 Jun 16 | 254 | -30 | 30 | 0 |
31 Mar 16 | 247 | -17 | 28 | 0 |
31 Dec 15 | 248 | -11 | 26 | 0 |
30 Sep 15 | 245 | -4 | 23 | 0 |
30 Jun 15 | 242 | 1 | 21 | 0 |
31 Mar 15 | 242 | 1 | 20 | 0 |
31 Dec 14 | 223 | -1 | 19 | 0 |
30 Sep 14 | 204 | 1 | 19 | 0 |
30 Jun 14 | 182 | -2 | 19 | 0 |
31 Mar 14 | 161 | -3 | 20 | 0 |
31 Dec 13 | 152 | -1 | 20 | 0 |
Quality Earnings: 0FDB has a large one-off loss of NOK11.3M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 0FDB's current net profit margins (3.7%) are lower than last year (6.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0FDB has become profitable over the past 5 years, growing earnings by 57.2% per year.
Accelerating Growth: 0FDB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0FDB had negative earnings growth (-36.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4.5%).
Return on Equity
High ROE: 0FDB's Return on Equity (7.4%) is considered low.